Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2022

View Archived Issues

P-selectin associated with COVID-19 severity and mortality

BMP-9 is required for survival after acute myocardial infarction

VBI Vaccines reports new preclinical data from coronavirus program VBI-2900

Targinta selects TARG-9 as drug candidate

Discovery may allow more selective chemokine targeting

NUAK1 inhibition as new antifibrotic treatment strategy

Elevated troponin in patients with COVID-19 is an independent risk factor for mortality

OPG is an independent factor for coronary artery calcification in hypertension

Shaanxi Micot Technology discloses new CaSR agonists

New HBV antiviral compounds patented by Janssen

Gasherbrum Bio presents new GLP-1 receptor agonists

Schroedinger identifies new CDC7 inhibitors

New SPNS2 inhibitors synthesized by University of Virginia

PEAR1 genetic variation tied to big endothelin levels in patients with acute myocardial infarction

Atreca announces agreement with Zymeworks and selection of new clinical candidate

Can-Fite developing topical formulation of piclidenoson for the treatment of psoriasis

NOX2 inhibition reverses obesity-induced atrial fibrillation

N-LIfT results in complete cell killing in solid tumor organoids

ACE2-independent blood cell infection linked to severe COVID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...